In addition, the frequency of CD41+ monocytes in the peripheral blood of tumor-bearing mice was significantly lower in myeloid FX or FXa-PAR2 signaling–deficient mice compared with the respective control mice (Figure 5F). This evidence concerns the gene F2RL1 and neoplasm.